|
Volumn 49, Issue 1, 2009, Pages 115-122
|
Elucidation of potential bortezomib response markers in mutliple myeloma patients
|
Author keywords
Biomarker; Bortezomib; Drug response; Efficacy; Pharmacodynamics; Velcade
|
Indexed keywords
APOLIPOPROTEIN C1;
APOLIPOPROTEIN C1';
BIOLOGICAL MARKER;
BORTEZOMIB;
M PROTEIN;
PEPTIDE;
PROTEIN;
UNCLASSIFIED DRUG;
ACCURACY;
ADULT;
AGED;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL EVALUATION;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DRUG EFFICACY;
DRUG RESPONSE;
FEMALE;
HUMAN;
LIQUID CHROMATOGRAPHY;
MALE;
METABOLISM;
MONOTHERAPY;
MULTIPLE CYCLE TREATMENT;
MULTIPLE MYELOMA;
PATHOPHYSIOLOGY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEIN ANALYSIS;
PROTEIN BLOOD LEVEL;
TANDEM MASS SPECTROMETRY;
TREATMENT DURATION;
TREATMENT RESPONSE;
AGED;
ANTINEOPLASTIC AGENTS;
APOLIPOPROTEIN C-I;
BIOLOGICAL MARKERS;
BLOOD PROTEINS;
BORONIC ACIDS;
CHROMATOGRAPHY, LIQUID;
CLINICAL TRIALS, PHASE II AS TOPIC;
DISEASE PROGRESSION;
FEMALE;
HUMANS;
MALE;
MASS SPECTROMETRY;
MIDDLE AGED;
MOLECULAR WEIGHT;
MULTIPLE MYELOMA;
PROTEIN ISOFORMS;
PYRAZINES;
REFERENCE STANDARDS;
REPRODUCIBILITY OF RESULTS;
SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;
TANDEM MASS SPECTROMETRY;
TIME FACTORS;
|
EID: 58649102059
PISSN: 07317085
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jpba.2008.09.053 Document Type: Article |
Times cited : (18)
|
References (23)
|